Article
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer.
Current oncology reports - 1 May 2017
Jeselsohn Rinath, De Angelis Carmine, Brown Myles, Schiff Rachel
Abstract excerpt
Recurrent ligand-binding domain ESR1 mutations have recently been detected in a substantial number of patients with metastatic ER+ breast cancer and evolve under the selective pressure of endocrine treatments. In this review, we evaluate the current understanding of the biological and clinical significance of these mutations. The preclinical studies revealed that these mutations lead to constitutive...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.